Translational Regenerative Medicine Market to grow with a CAGR of 9.70% During Forecast Period
Increasing healthcare
infrastructure and a supportive regulatory environment are the major drivers
for the Global Translational Regenerative Medicine Market.
According to TechSci Research
report, “Global Translational Regenerative Medicine Market Industry Size, Share, Trends, Competition,
Opportunity and Forecast, 2018-2028”, Global Translational
Regenerative Medicine Market has valued at USD 2.72 billion in 2022 and is
anticipated to witness an impressive growth in the forecast period with a CAGR
of 9.63%. This can be due to
collaborations and partnerships among leading companies with a diverse approach
to merge the expertise of individual companies and to strengthen their position
in the market.
Gene editing technologies are
a group of molecular tools and techniques that enable scientists to modify the
DNA of living organisms, including humans. These technologies have
revolutionized the fields of genetics, biotechnology, and medicine, offering
the ability to precisely add, delete, or replace genetic material within an
organism's genome. TALENs (Transcription Activator-Like Effector Nucleases) are
another gene editing technology that can be used to modify DNA sequences.
TALENs are engineered proteins that can be programmed to recognize specific DNA
sequences. When combined with a nuclease enzyme, TALENs can be used to induce
double strand breaks in the DNA, which can be repaired with desired changes. Zinc
Finger Nucleases (ZFNs) are customizable proteins that can be engineered to
bind to specific DNA sequences. Like TALENs, they are used in combination with
a nuclease enzyme to create double strand breaks in the DNA, facilitating gene
editing. In addition to the above techniques, various synthetic biology tools
and platforms enable the design and construction of custom genetic circuits and
pathways for specific applications, such as metabolic engineering or
bioproduction.
Even after approval, monitoring the long-term
safety and effectiveness of regenerative therapies is crucial. Post-market
surveillance helps identify any unexpected adverse events and ensures ongoing
patient safety. Ensuring that patients have access to
regenerative therapies is a key aspect of translational regenerative medicine.
This involves addressing issues related to affordability, reimbursement, and
equitable access. Healthcare professionals involved in translational
regenerative medicine require specialized training and expertise to provide
these therapies safely and effectively.
Browse over XX market data Figures and spread through 110 Pages and an in-depth TOC on "Global Translational Regenerative Medicine Market”
In
April 2023, Institute for Regenerative Medicine Opens at Mount Sinai. The
institute, which now has three additional centers, will spearhead research to
promote original findings and investigate fresh approaches to treating a
variety of illnesses, from leukemia to Alzheimer's disease. Generative
medicine, which is the replacement, engineering, or regeneration of human
cells, tissues, or organs, holds tremendous promise for the medical industry.
In the future, it might be feasible to mend injured nerve cells, create a new
kidney in a petri dish, or stop memory loss. Across Mount Sinai's fundamental
scientific and clinical departments, the Institute will enhance and organize
research and education in broad areas of regenerative biology and medicine. It
will also include three centers, each of which will concentrate on a particular
group of illnesses and disorders. Alper Centre for Neural Development and
Regeneration, Centre for Epithelial and Airway Biology and Regeneration, and
Centre for Advancement of Blood Cancer Therapies will also be part of the
Institute.
Ethical
and moral considerations are significant challenges in the field of global
translational regenerative medicine. These considerations encompass a range of
ethical dilemmas and moral questions that researchers, healthcare
professionals, policymakers, and society at large must grapple with. One of the most prominent ethical debates in regenerative
medicine relates to the use of embryonic stem cells. Harvesting these cells
often requires the destruction of human embryos, raising questions about the
moral status of embryos and the rights of unborn life. Ensuring that patients fully understand
the nature of regenerative therapies, including potential risks and benefits,
is critical. Obtaining informed consent, especially in the context of
experimental treatments or unproven therapies, can be complex and challenging.
Regenerative therapies, especially those involving gene editing and stem cell
transplantation, may carry unknown risks. Balancing the potential benefits with
the safety of patients is a moral responsibility.
Global Translational Regenerative Medicine
Market segmentation is based on Product type, application, and Region
Based on Product type, Global
Translational Regenerative Medicine Market is segmented into Cell Based
Product, Gene Therapy Product, Tissue Engineered Product. A tissue-engineered product
in translational regenerative medicine refers to a biomedical product that has
been created by combining living cells, biomaterials, and biologically active
molecules to mimic or replace damaged or lost tissues or organs in the human
body. These products are designed to promote tissue regeneration and functional
restoration, making them a crucial component of regenerative medicine.
Tissue-engineered products typically involve the use of various types of cells,
such as stem cells, primary cells, or cell lines, depending on the specific
application. These cells may be obtained from the patient's own body (autologous)
or from other sources (allogeneic or xenogeneic). Scaffolds or matrices made
from biomaterials are used as a structural framework to support cell
attachment, growth, and tissue formation. These biomaterials are designed to be
biocompatible, biodegradable, and capable of providing mechanical support.
Growth factors, cytokines, and other signaling molecules are often incorporated
into tissue-engineered products to stimulate cell proliferation,
differentiation, and tissue regeneration. These molecules play a crucial role
in promoting the desired biological responses.
Based on Region, North America dominated the Global Translational
Regenerative Medicine Market.
The United States has established a regulatory framework, including the Food
and Drug Administration (FDA), that has provided a pathway for the approval and
commercialization of regenerative medicine products. Regulatory clarity and
guidelines have attracted investment and research efforts. North America has a
well-developed system for protecting intellectual property, which has
encouraged innovation in the regenerative medicine field. Companies and
researchers have been able to secure patents and protect their discoveries. The
availability of venture capital and private equity funding in North America has
attracted start-ups and emerging companies focused on regenerative medicine,
driving market growth. The region has a large and aging population with a high
prevalence of chronic diseases and conditions that could benefit from regenerative
therapies. The demand for innovative medical solutions has contributed to the
growth of the regenerative medicine market in the region.
Asia-pacific region to fastest growth in
the Global Translational Regenerative Medicine Market. The Asia-Pacific region
is home to a significant portion of the world's population, including both
developed and emerging economies. This large and diverse population creates a
substantial patient base for regenerative medicine therapies. Like many other
parts of the world, APAC has an aging population with a higher prevalence of
age-related diseases and conditions. This demographic shift drives the demand
for regenerative therapies that can address these health challenges. Many APAC
countries have been increasing their healthcare budgets and investments in
medical research and innovation. This includes funding for regenerative
medicine research and development. Several countries in APAC, such as China,
India, and South Korea, have rapidly growing economies. These emerging
economies are investing in biotechnology and life sciences sectors, fostering
innovation in regenerative medicine.
Some of the major companies
operating in the Global Translational Regenerative Medicine Market include:
- Astellas Pharma Inc.
- Athersys, Inc.
- AVITA Medical
- Axogen Corporation
- Gamida Cell Ltd.
- Integra LifeSciences Corporation
- Medtronic PLC
- Mesoblast Ltd.
- Novartis AG
- Spark Therapeutics Inc.
Download Free Sample Report
Customers
can also request 10% free customization on this report.
“Certain
areas, particularly in North America, are projected to exert significant demand
for gene therapies. The growth in the competitive landscape and the presence of
well-established companies in the market, committed to enhance the overall
wellbeing of people each year, are expected to contribute to a remarkable
growth of the Global Translational Regenerative Medicine Market in the forecast
period," said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based Global management consulting firm.
Translational Regenerative Medicine Market – Global
Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented
by Product Type (Cell Based Product, Gene Therapy Product, Tissue Engineered
Product), by Application (Cardiovascular, Dermatology, Diabetes, Neurology,
Oncology, Orthopedic), by region, and Competition evaluated
the future growth potential of Global Translational Regenerative Medicine
Market and provides statistics & information on market size, structure, and
future market growth. The report intends to provide innovative market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Translational
Regenerative Medicine Market.
Contact
Mr. Ken Mathews
TechSci Research
LLC
420 Lexington Avenue,
Suite 300, New
York,
United States-
10170,
M: +13322586602
Email: [email protected]
Website: https://www.techsciresearch.com